NCT07422389|Unknown
BRM421 Ophthalmic Solution in Patients With Limbal Stem Cell Deficiency
Intermediate-Size Patient Population Use of BRM421 Ophthalmic Solution in Patients With Limbal Stem Cell Deficiency
Loading search results
Intermediate-Size Patient Population Use of BRM421 Ophthalmic Solution in Patients With Limbal Stem Cell Deficiency
Sponsor study identifier
Secondary identifiers
OTHER · BRIM Biotechnology
expanded_access
N/A
1 country
1
Study Start
Not reported
Date not reportedPrimary Completion
Not reported
Date not reportedStudy Completion
Not reported
Date not reportedThe goal of this program is to provide patients with Limbal Stem Cell Deficiency access to the BRM421 eye drops. Participants will:
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 2, 2025
Actual (reported)February 20, 2026
Actual (reported)Patients eligible to participate will receive 0.06% BRM421 Ophthalmic Solutions to be administered two times daily (BID, morning and bedtime) on the eligible eye(s). The administration will be at least 12 weeks. The investigator may continue the treatment beyond the 12 weeks based on clinical response. For patients scheduled for LSC transplant, treatment with BRM421 should start only after surgery.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Scheie Eye Institute
Philadelphia, Pennsylvania, 19104, United States
First Submitted
December 2, 2025
First Posted
February 20, 2026
Last Updated
February 20, 2026
Record last verified: 2026-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Autologous Transplantation of Cultivated Limbal Stem Cells on Amniotic Membrane in Limbal Stem Cell Deficiency (LSD) Patients
Contact the study team to confirm eligibility.